目的 研究參蓮膠囊聯(lián)合ECF方案（注射用鹽酸表柔比星、順鉑注射液和氟尿嘧啶注射液）治療晚期胃癌的臨床療效。方法 選取2017年5月—2019年5月在河南科技大學(xué)第一附屬醫(yī)院治療的80例晚期胃癌患者，將所有患者隨機(jī)分為對(duì)照組和治療組，每組各40例。對(duì)照組患者給予ECF方案，第1天靜脈滴注順鉑注射液60 mg/m²；第1天靜脈滴注注射用鹽酸表柔比星50 mg/m²；靜脈滴注氟尿嘧啶注射液200 mg/m²，1次/d。治療組在對(duì)照組基礎(chǔ)上口服參蓮膠囊，6粒/次，3次/d。21 d為1個(gè)治療周期，兩組患者持續(xù)治療3個(gè)治療周期。觀察兩組患者客觀緩解率（ORR）和疾病控制率（CBR）、Karnofsky（KPS）評(píng)分、血清腫瘤標(biāo)志物水平和不良反應(yīng)。結(jié)果 治療后，對(duì)照組ORR和CBR分別為37.50%、52.50%；治療組ORR和CBR分別為55.00%、65.00%；治療組顯著高于對(duì)照組（P<0.05）。治療后，兩組患者KPS評(píng)分均明顯升高（P<0.05）；且治療組KPS評(píng)分升高較明顯（P<0.05）。治療后，兩組血清癌胚抗原（CEA）、糖鏈抗原199（CA199）、胃癌抗原（CA724）水平顯著降低（P<0.05）；并且治療組血清CEA、CA199、CA724水平降低較明顯（P<0.05）。治療后，治療組中性粒細(xì)胞減少、血小板減少、肝損傷、惡心嘔吐等不良反應(yīng)明顯較低（P<0.05）。結(jié)論 參蓮膠囊聯(lián)合ECF方案治療晚期胃癌具有較好的臨床療效，能夠提高生活質(zhì)量，降低腫瘤標(biāo)志物水平，安全性較好。

Objective To study efficacy of Shenlian Capsules combined with ECF chemotherapy regimen (Epirubicin Hydrochloride for injection, Cisplatin Injection and Fluorouracil Injection) in treatment of advanced gastric cancer. Methods Patients (80 cases) with advanced gastric cancer in the First Affiliated Hospital of Henan University of Science and Technology from May 2017 to May 2019 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were given ECF chemotherapy regimen:Cisplatin Injection was intravenously injected with 60 mg/m² at the first day, Epirubicin Hydrochloride for injection was intravenously injected with 50 mg/m² at the first day, and Fluorouracil Injection was intravenously injected with 200 mg/m², once daily. Patients in the treatment group were po administered with Shenlian Capsules on the basis of the control group, 6 grains/time, three times daily. A treatment cycle had 21 d, and patients in two groups were treated for 3 cycles. After treatment, the clinical efficacies were evaluated, and ORR, CBR, KPS score, serum tumor markers and adverse reactions in two groups were compared. Results After treatment, ORR and CBR of the control group were 37.50% and 52.50%, respectively; ORR and CBR of the treatment group were 55.00% and 65.00%, respectively; and the indexes of the treatment group were significantly higher than those of the control group (P<0.05). After treatment, the KPS scores of two groups were significantly increased (P<0.05), and the KPS score of the treatment group was significantly higher than that of the control group (P<0.05). After treatment, the serum levels of CEA, CA199, and CA724 in two groups were significantly decreased (P<0.05), and the serum levels of CEA, CA199, and CA724 in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the adverse reactions of neutrophilia, thrombocytopenia, liver injury, nausea, and vomiting in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shenlian Capsules combined with ECF chemotherapy regimen has clinical curative effect in treatment of advanced gastric cancer, can improve the quality of life, and reduce the level of tumor markers, with good safety.

R979.1